Azienda Sanitaria Locale Roma 1
- Address
- Borgo Santo Spirito 3, 00193 Rome, Italy
Azienda Sanitaria Locale Roma 1 - Multidisciplinary Clinical Research Center
Azienda Sanitaria Locale Roma 1 is a comprehensive healthcare institution conducting advanced clinical research across multiple therapeutic areas. The center demonstrates particular expertise in neurological disorders, cardiovascular diseases, and hematologic malignancies, with a strong focus on evaluating novel therapeutic interventions in complex patient populations.
- Neuromuscular and demyelinating disorders including myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and radiologically isolated syndrome
- Cardiovascular research focused on heart failure management, particularly in patients with ischemic heart disease
- Hematologic oncology specializing in multiple myeloma and relapsed/refractory disease states
- Autoimmune and inflammatory conditions including psoriatic arthritis and dactylitis management
The research center participates in sophisticated Phase III clinical trials evaluating both novel biologics and innovative therapeutic combinations. Their neurological research portfolio includes groundbreaking studies examining vaccine applications in radiologically isolated syndrome and complement inhibition in neuromuscular diseases. The cardiovascular program investigates repurposed medications like colchicine and thiamine for heart failure management, while the rheumatology division focuses on ultrasound-guided assessment of biologic therapies in psoriatic arthritis. This diverse clinical trial portfolio positions Azienda Sanitaria Locale Roma 1 as a significant contributor to advancing treatment options across multiple medical specialties.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Roma 1
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial | Dianthus Therapeutics Inc. | Phase III | Recruiting | Aug 2025 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Colchicine | 1 | Unknown | 2025-01-23 | 2025-01-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.